1. Molecular Therapy - Nucleic Acids
Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice 
Rosie Z Yu, Mark J Graham, Noah Post, Stan Riney, Thomas Zanardi, Shannon Hall, Jennifer Burkey, Colby S Shemesh, Thazha P Prakash, Punit P Seth, Eric E Swayze, Richard S Geary, Yanfeng Wang, Scott Henry 
Molecular Therapy - Nucleic Acids 
Volume 5, (January 2016)
DOI: /mtna
Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

2. Figure 1
Chemical structure of ISIS and ISIS Note, ISIS is uncongugated ISIS , i.e., contains the 20 nucleotides only without GalNAc3-THA. ISIS has uniform phosphorothioate linkages.
Molecular Therapy - Nucleic Acids 2016 5, DOI: ( /mtna )
Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

3. Figure 2
Comparison of dose–response curves of GalNAc-conjugated antisense oligonucleotides (ASO) (ISIS ) and uncongugated ASO (ISIS ) for liver Apo(a) mRNA (a) and plasma Apo(a) protein (b) (2 days after last treatment) following 6 weeks of subcutaneous administrations in human transgenic mice.
Molecular Therapy - Nucleic Acids 2016 5, DOI: ( /mtna )
Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

4. Figure 3
Concentration–time profiles of ISIS in plasma, liver, and kidneys following the last dose of multiple subcutaneous administrations of ISIS at 140 mg/kg for 4 weeks in mice hour profiles. Error bars represent standard deviation (N = 3 per time point).
Molecular Therapy - Nucleic Acids 2016 5, DOI: ( /mtna )
Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

5. Figure 4
Plasma concentration–time profiles of fully conjugated, partially conjugated (with 1, 2, or 3 sugar deletions), and unconjugated ISIS following repeated subcutaneous injections of 4 mg/kg (a) and 140 mg/kg (b) ISIS in mice.
Molecular Therapy - Nucleic Acids 2016 5, DOI: ( /mtna )
Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

6. Figure 5
Concentration–time profiles of fully conjugated, partially conjugated (with 1, 2, or 3 sugar deletions), and unconjugated ISIS in liver (a) and kidney (b) following multiple (day 28) subcutaneous injections of 4 mg/kg fully conjugated ISIS in mice. Error bars represent standard deviation (n = 3).
Molecular Therapy - Nucleic Acids 2016 5, DOI: ( /mtna )
Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

7. Figure 6
Mean relative percent of unconjugated ISIS (full-length) and shortmer metabolites in liver and kidney cortex 48 hours following 4 weeks of treatment (day 30) of 140 mg/kg/week ISIS in mice. N = Unconjugated ISIS Error bars represent standard deviation (n = 9).
Molecular Therapy - Nucleic Acids 2016 5, DOI: ( /mtna )
Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions